Eli Lilly extends tender offer deadline for Point Biopharma shares on low participation
Reuters
Published Dec 04, 2023 07:21AM ET
Updated Dec 05, 2023 04:36AM ET
(Reuters) - Eli Lilly (NYSE:LLY) on Monday again extended its deadline for Point Biopharma Global shareholders to sell their shares to the drugmaker, following low participation amid investor concerns that the offer price was low.
Lilly set Dec. 15 as the deadline in a third extension. The Indianapolis-based drugmaker maintained its offer price at $12.50 per share, which is over 10% lower than Point Biopharma's last closing price of $13.80.
Lilly had struck a $1.4 billion deal to buy Point Biopharma in October. Since then till Friday's close, shares of Point Biopharma have more than doubled.
Biotechnology Value Fund, a private investment firm which owns 16.4% of Point Biopharma, had said in a filing last month that closing the deal ahead of imminent results from a late-stage study of a key drug candidate was "not in the best interest" on the company's shareholders.
As of Friday 5 p.m. ET, about 26.4 million shares had been validly tendered, representing only 24.75% of the issued and outstanding shares of Point Biopharma, Lilly said on Monday. The participation was lower than the 26.45% as of Nov. 16.
Shares of Point Biopharma were down 0.1% at $13.76 in early trading, while Lilly also traded marginally lower.
Point Biopharma is a developer of radioligand therapy, a targeted cancer treatment which uses a combination of molecules that attach themselves to the tumors and radioactive particles that kill the specific cells.
The company expects results from its late-stage study of experimental therapy, PNT2002, to treat a type of advanced prostate cancer later this month.
TD Cowen analyst Boris Peaker estimated there is a 60% chance of positive results from the study, which is likely to lift the stock further.
Lilly will then need to raise its offer, with a second bidder also likely, Peaker said in a note last month.
Get The News You Want
Written By: Reuters
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.